Stephen C Hyde
Overview
Explore the profile of Stephen C Hyde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1049
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davies J, Polineni D, Boyd A, Donaldson S, Gill D, Griesenbach U, et al.
Am J Respir Crit Care Med
. 2024 Sep;
210(12):1398-1408.
PMID: 39236265
Cystic fibrosis (CF) is a genetic disease caused by mutations in the (cystic fibrosis transmembrane conductance regulator) gene. Although CF is a multiorgan disease, the leading causes of morbidity and...
2.
Moiseenko A, Sinadinos A, Sergijenko A, Pineault K, Saleh A, Nekola K, et al.
Eur Respir J
. 2024 Aug;
65(1).
PMID: 39174284
Rationale And Objective: Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CFTR modulators offer significant improvements, but ∼10% of patients remain nonresponsive or...
3.
Ogger P, Martin M, Michalaki C, Zhou J, Brown J, Du Y, et al.
Eur J Immunol
. 2022 Sep;
52(11):1768-1775.
PMID: 36106692
SARS-CoV-2 is a newly emerged coronavirus, causing the global pandemic of respiratory coronavirus disease (COVID-19). The type I interferon (IFN) pathway is of particular importance for anti-viral defense and recent...
4.
McLachlan G, Alton E, Boyd A, Clarke N, Davies J, Gill D, et al.
Hum Gene Ther
. 2022 Sep;
33(17-18):893-912.
PMID: 36074947
The prospect of gene therapy for inherited and acquired respiratory disease has energized the research community since the 1980s, with cystic fibrosis, as a monogenic disorder, driving early efforts to...
5.
Munday R, Coradin T, Nimmo R, Lad Y, Hyde S, Mitrophanos K, et al.
Mol Ther Methods Clin Dev
. 2022 Jul;
26:239-252.
PMID: 35892086
A lentiviral vector (LV) pseudotype derived from the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins of a murine respirovirus (Sendai virus) facilitates efficient targeting of murine lung . Since targeting of...
6.
Lund-Palau H, Juarez-Molina C, Meng C, Bhargava A, Pilou A, Aziz K, et al.
Mol Ther Methods Clin Dev
. 2022 May;
25:382-391.
PMID: 35573048
We developed a novel lentiviral vector, pseudotyped with the F and HN proteins from Sendai virus (rSIV.F/HN), that produces long-lasting, high-efficiency transduction of the respiratory epithelium. Here we addressed whether...
7.
Du Y, Zhang S, Zhang Z, Miah K, Wei P, Zhang L, et al.
Front Immunol
. 2022 May;
13:819058.
PMID: 35529866
Vaccines for COVID-19 are now a crucial public health need, but the degree of protection provided by conventional vaccinations for individuals with compromised immune systems is unclear. The use of...
8.
Du Y, Miah K, Habib O, Meyer-Berg H, Conway C, Viegas M, et al.
Thorax
. 2022 Feb;
77(12):1229-1236.
PMID: 35165144
Background: The COVID-19 pandemic continues to be a worldwide threat and effective antiviral drugs and vaccines are being developed in a joint global effort. However, some elderly and immune-compromised populations...
9.
Munis A, Wright B, Jackson F, Lockstone H, Hyde S, Green C, et al.
Mol Ther Methods Clin Dev
. 2022 Jan;
24:62-70.
PMID: 34977273
Understanding pulmonary diseases requires robust culture models that are reproducible, sustainable in long-term culture, physiologically relevant, and suitable for assessment of therapeutic interventions. Primary human lung cells are physiologically relevant...
10.
Downes D, Cross A, Hua P, Roberts N, Schwessinger R, Cutler A, et al.
Nat Genet
. 2021 Nov;
53(11):1606-1615.
PMID: 34737427
The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) disease (COVID-19) pandemic has caused millions of deaths worldwide. Genome-wide association studies identified the 3p21.31 region as conferring a twofold increased risk...